Literature DB >> 18158566

Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.

Gergely Varga1, Judit Kiss, Judit Várkonyi, Virág Vas, Péter Farkas, Katalin Pálóczi, Ferenc Uher.   

Abstract

Myelodysplastic syndromes (MDSs) are a heterogeneous group of hematological disorders characterized by ineffective hematopoiesis, enhanced bone marrow apoptosis and frequent progression to acute myeloid leukemia. Several recent studies suggested that, besides the abnormal development of stem cells, microenvironmental alterations are also present in the MDS bone marrow. In this study, we have examined the relative frequencies of stem and progenitor cell subsets of MDS and normal hematopoietic cells growing on stromal cell layers established from MDS patients and from normal donors. When hematopoietic cells from MDS patients were co-cultured with normal stromal cells, the frequency of either early or late cobblestone area-forming cells (CAFC) was significantly lower compared to the corresponding normal control values in 4 out of 8 patients. In the opposite situation, when normal hematopoietic cells were incubated on MDS stromal cells, the CAFC frequencies were decreased in 5 out of 6 patients, compared to normal stromal layer-containing control cultures. Moreover, a soluble Notch ligand (Jagged-1 protein) was an inhibitor of day-35-42 CAFC when normal hematopoietic cells were cultured with normal or MDS stromal cells, but was unable to inhibit MDS stem and early progenitor cell growth (day-35-42 CAFC) on pre-established stromal layers. These findings suggest that in early hematopoietic cells isolated from MDS patients the Notch signal transduction pathway is disrupted. Furthermore, there was a marked reduction in the plasticity of mesenchymal stem cells of MDS patients compared with those of normal marrow donors, in neurogenic and adipogenic differentiation ability and hematopoiesis supporting capacity in vitro. These results are consistent with the hypothesis that when alterations are present in the myelodysplastic stroma environment along with intrinsic changes in a hematopoietic stem/progenitor cell clone, both factors might equally contribute to the abnormal hematopoiesis in MDS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18158566     DOI: 10.1007/bf02940310

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  33 in total

Review 1.  Notch signalling in hematopoiesis.

Authors:  K Ohishi; N Katayama; H Shiku; B Varnum-Finney; I D Bernstein
Journal:  Semin Cell Dev Biol       Date:  2003-04       Impact factor: 7.727

2.  Soluble Jagged-1 is able to inhibit the function of its multivalent form to induce hematopoietic stem cell self-renewal in a surrogate in vitro assay.

Authors:  Virág Vas; László Szilágyi; Katalin Pálóczi; Ferenc Uher
Journal:  J Leukoc Biol       Date:  2004-01-23       Impact factor: 4.962

3.  Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling.

Authors:  B Varnum-Finney; L Xu; C Brashem-Stein; C Nourigat; D Flowers; S Bakkour; W S Pear; I D Bernstein
Journal:  Nat Med       Date:  2000-11       Impact factor: 53.440

4.  Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization.

Authors:  Eugenia Flores-Figueroa; Rosa Maria Arana-Trejo; Guillermo Gutiérrez-Espíndola; Adrián Pérez-Cabrera; Hector Mayani
Journal:  Leuk Res       Date:  2005-02       Impact factor: 3.156

Review 5.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

6.  Cellular analysis of growth suppression induced by the Notch ligands, Delta-1 and Jagged-1 in two myeloid leukemia cell lines.

Authors:  Mai Murata-Ohsawa; Shuji Tohda; Nobuo Nara
Journal:  Int J Mol Med       Date:  2004-08       Impact factor: 4.101

Review 7.  Multiple niches for Notch in cancer: context is everything.

Authors:  Andrew P Weng; Jon C Aster
Journal:  Curr Opin Genet Dev       Date:  2004-02       Impact factor: 5.578

8.  Overexpression of delta-like (Dlk) in a subset of myelodysplastic syndrome bone marrow trephines.

Authors:  Florian Länger; Juliane Stickel; Mathewos Tessema; Hans Kreipe; Ulrich Lehmann
Journal:  Leuk Res       Date:  2004-10       Impact factor: 3.156

Review 9.  The myelodysplastic syndrome(s): a perspective and review highlighting current controversies.

Authors:  David P Steensma; Ayalew Tefferi
Journal:  Leuk Res       Date:  2003-02       Impact factor: 3.156

Review 10.  Notch regulation of lymphocyte development and function.

Authors:  Freddy Radtke; Anne Wilson; Stephane J C Mancini; H Robson MacDonald
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

View more
  19 in total

Review 1.  The inflammatory microenvironment in MDS.

Authors:  Lili Yang; Yaqin Qian; Erika Eksioglu; Pearlie K Epling-Burnette; Sheng Wei
Journal:  Cell Mol Life Sci       Date:  2015-02-08       Impact factor: 9.261

2.  Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.

Authors:  Ruben A Ferrer; Manja Wobus; Catrin List; Rebekka Wehner; Claudia Schönefeldt; Barbara Brocard; Brigitte Mohr; Martina Rauner; Marc Schmitz; Maik Stiehler; Gerhard Ehninger; Lorenz C Hofbauer; Martin Bornhäuser; Uwe Platzbecker
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

Review 3.  Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation.

Authors:  Charalampos Pontikoglou; Frédéric Deschaseaux; Luc Sensebé; Helen A Papadaki
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

4.  Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome.

Authors:  Youshan Zhao; Dong Wu; Chengming Fei; Juan Guo; Shuncheng Gu; Yang Zhu; Feng Xu; Zheng Zhang; Lingyun Wu; Xiao Li; Chunkang Chang
Journal:  Haematologica       Date:  2014-10-31       Impact factor: 9.941

Review 5.  Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis.

Authors:  Marc H G P Raaijmakers
Journal:  Int J Hematol       Date:  2012-01-06       Impact factor: 2.490

6.  Impaired osteogenic differentiation of mesenchymal stem cells derived from bone marrow of patients with lower-risk myelodysplastic syndromes.

Authors:  Chengming Fei; Youshan Zhao; Shucheng Gu; Juan Guo; Xi Zhang; Xiao Li; Chunkang Chang
Journal:  Tumour Biol       Date:  2014-01-19

Review 7.  The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.

Authors:  Allison J Li; Laura M Calvi
Journal:  Exp Hematol       Date:  2017-08-18       Impact factor: 3.084

8.  Notch-Hes pathway mediates the impaired osteogenic differentiation of bone marrow mesenchymal stromal cells from myelodysplastic syndromes patients through the down-regulation of Runx2.

Authors:  Chengming Fei; Juan Guo; Youshan Zhao; Shucheng Gu; Sida Zhao; Xiao Li; Chunkang Chang
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 9.  Notch signaling in the malignant bone marrow microenvironment: implications for a niche-based model of oncogenesis.

Authors:  Andrew G Evans; Laura M Calvi
Journal:  Ann N Y Acad Sci       Date:  2014-10-28       Impact factor: 5.691

10.  Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration.

Authors:  J C Huang; S K Basu; X Zhao; S Chien; M Fang; V G Oehler; F R Appelbaum; P S Becker
Journal:  Blood Cancer J       Date:  2015-04-10       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.